JC06 Rec'd PCT/PTO 20 SEP 2005

ORM PTO-1390 (Modified) ATTORNEY'S DOCKET NUMBER U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE PA0304 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/GB2003/003876 2 April 2003 8 September 2003 TITLE OF INVENTION DETERMINING CELL CYCLE PHASE DATA APPLICANT(S) FOR DO/EO/US ARINI, Nicholas S.; GOODYER, Ian D.; and ZALTSMAN, Alla B. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 1. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. 4.  $\bowtie$ The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). b. 🛛 has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. b. 🖂 has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).  $\boxtimes$ 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409).  $\boxtimes$ A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification.  $\boxtimes$ 18. A power of attorney and/or change of address letter. X 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 21.  $\boxtimes$ 22. Express Mail Label No. EV 430343668 US X 23. Other items or information: copy of this transmittal letter for charging purposes, Certificate of Mailing by Express Mail, copy of the GB Search Report, copies of

filing the sequence listing (2pgs) and a return postcard

the non-US publications cited on the Information Disclosure Statement, paper copy of the sequence listing (1pg), required statements for

Local PET PTO 2.0 SEP 2005 PTO-1390 (Rev. 02-2005)

"Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLEAT DN NOTIFERON, SEC 2 CF 1.5) INTERNATIONAL APPLICATION NO					ICATION NO.	ATTORNEY'S DOCKET NUMBER	
to be assigned PCT/GB2003/003876					03876	PA0304	
The following fees are submitted:						CALCULATIONS	PTO USE
24. 🛛 Basic national fee						\$ \$300.00	
25.   Examination fee  If International preliminary examination report prepared by USPTO and all claims							
satisfy provisions of PCT Article 33(1)-(4)\$100						\$ \$200.00	
All other situations. \$200							
26. Search fee							
the USPTO as an International Searching Authority							
International Search Report prepared and provided to the Office						\$ \$400.00	
TOTAL OF 24, 25 and 26 =						\$ \$900.00	<del> </del>
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole					
- 100 =	0 /50 =	0			× \$250.00	\$ \$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						\$	
CLAIMS	NUMBER F	NUMBER FILED NUMBER EXTRA			RATE		
Total claims	25	- 20 =	5	х	\$50.00	\$ \$250.00	
Independent clair	ns 1	- 3=	0	x	\$200.00	\$ \$0.00	
MULTIPLE DEPENDENT CLAIMS (if applicable)						\$ \$0.00	
TOTAL OF ABOVE CALCULATIONS =						\$ \$1,150.00	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						\$ \$0.00	
<del></del>						\$ \$1,150.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$ \$0.00	
						\$ \$1,150.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$ \$0.00	
		\$ \$1,150.00					
						Amount to be	\$
						Amount to be	\$
a.	in the amount of \$						
b. X Please charge my Deposit Account No. 502-590 in the amount of \$1,150.00 to cover the above fees.  A duplicate copy of this sheet is enclosed.							
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 502-590 . A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status							
	RESPONDENCE T	MA	$a(Z \mid $				
Customer No.: 22840 SIGNATURE						1 CASTINITY	
Amersham Biosciences Corp Royal N. R						<i>y</i>	
Patent Department NAME							
Piscataway, New Jersey 08855 32,529							i
(732) 457-8423						ION NUMBER	<del></del>